Vertex achieves 2 main goals of late-stage trial for rheumatoid arthritis

| September 7, 2011

Vertex Pharmaceuticals (NASDAQ:VRTX) reported Tuesday its experimental drug VX-509 for the treatment of rheumatoid arthritis met its two primary endpoints during a late-stage, 12-week trial. According to results, VX-509 resulted in substantial and statistically significant improvements in rheumatoid arthritis activity, compared to a placebo during the phase 2a trial. Rheumatoid arthritis is a chronic inflammatory [...]

Category: Activity | Comments Off
Tags:

RLPC-Rising European bank funding costs threaten M&A

| September 7, 2011

* Europes dollar squeeze puts dampener on cross-border Mamp;A * European banks say no to uneconomic loans * Interest margins, utilisation fees boosted By Tessa Walsh LONDON, Sept 6 (Reuters) – European banks are trying to pass on increased funding costs to companies in Europe, the Middle East and Africa on expensive dollar loans and [...]

Category: Funding | Comments Off
Tags: